SL Science’s Post

At SL Science Holding Limited (Nasdaq: SLBT), we believe the future of oncology lies within the immune system itself. Our Gamma Delta T (GDT) cell therapy platform is designed to do what conventional treatments struggle with — precisely targeting solid tumors like pancreatic and brain cancers, triggering destruction from within, while leaving healthy tissue unharmed. This isn't about introducing a foreign substance. It's about empowering your own immune cells to work smarter. We're advancing next-generation, off-the-shelf cellular therapies to make this accessible — for patients who are still waiting. #SLScience #SLBT #Nasdaq #GDT #CellTherapy #Immunooncology #SolidTumors #PancreaticCancer #BrainCancer